Healthcare / BiotechnologyStockholm
$5.86
-0.18 (-2.98%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-268.5M · quality 78.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
35/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-101.2%
↓Gross Margin
19.9%
↓Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+40.5%
FCF CAGR
—
FCF margin
-430.3%
FCF / Net income
0.78x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $62.4M · net income $-342.5M · FCF $-268.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $62.4M | $62.4M | $46.1M | $57.6M | $22.5M |
| Net Income | $-342.5M | $-342.5M | $-343.6M | $-326.9M | $-193.8M |
| EBITDA | $-290.2M | $-290.2M | $-322.1M | $-319.0M | $-191.0M |
| EPS | -0.90 | -0.90 | -1.10 | -1.30 | -1.00 |
| Gross Margin | 19.9% | 19.9% | 74.8% | 80.9% | -533.8% |
| Operating Margin | -528.8% | -528.8% | -698.0% | -540.5% | -876.0% |
| Net Margin | -548.9% | -548.9% | -745.3% | -567.5% | -861.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.24 | 0.21 | 0.01 |
| Current Ratio | 0.69 | 0.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-268.5M | $-268.5M | $-227.9M | $-278.4M | $-173.5M |
| Returns | |||||
| ROE | -101.2% | -101.2% | -69.7% | -59.9% | -38.3% |
| Valuation | |||||
| P/B | 6.46 | 6.46 | 4.33 | 2.74 | 2.77 |
| Growth & Yield | |||||
| Revenue Growth | 35.4% | 35.4% | -20.0% | 156.0% | — |
| EPS Growth | 18.2% | 18.2% | 15.4% | -30.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+88.1%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.10 → -0.90
Residual
+88.1%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.